Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient’s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.

Image information can be used to predict the molecular classification of patient tumour samples in colour, using state-of-the-art deep learning models in pathology © S:CORT

Colorectal cancer (CRC) currently has four known molecular subtypes which are identified on the basis of its RNA expression profile, using RNA analysis. But the process of RNA analysis is costly, technically challenging and it requires a specialist to interpret data to determine the subtype. In order to more efficiently and cheaply determine the molecular subtype of a patient’s CRC, there is a need to use more easily-acquired data on a tumour and categorise its subtype based on an automated technique.

One prevalent source of data in cancer diagnostics is images, such as histological images of the microscopic anatomy of a cancer. Almost all CRC patients already have a sample of their tumour inspected by a pathologist as part of their standard care.

A new paper published by Dr Korsuk Sirinukunwattana, Dr Enric Domingo, Prof Viktor H Koelzer & Prof Jens Rittscher from the Stratification in Colorectal Cancer consortium (S:CORT), has demonstrated the potential for using these images to determine molecular subtype.

Through the training of a deep-learning neural network, using over 1,000 tumour samples, the team discovered that AI could be trained to distinguish between the four molecular subtypes using images alone.

Usually, histological images are a modest indicator of how colorectal cancers have progressed, and there is currently no way to determine the molecular subtype of a tumour by the human eye alone, without doing a gene profile on tumour samples. However, this new study demonstrates that technology can be trained to identify the minute morpho-molecular differences between molecular subtypes.

This new concept, called Image-based Consensus Molecular Subtyping (imCMS), will allow images to be interpreted through association of tile-level predictions with morphology, molecular features and outcome data.

Furthermore, this study also demonstrated that AI is able to classify the molecular subtype of samples that were previously unclassifiable by the standard process of RNA expression profiling. It also provides information for the spatial distribution of each subtype within a tumour.

This AI technology will have huge implications on the standardisation of classifying molecular subtypes of CRC.

More details can be found on the CRUK Oxford Centre website

Similar stories

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Advancing radiotherapy technology through clinical trials

Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.

Oxford cancer clinical trials unit receives acclaimed nursing award

The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS

A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.